MAXIGESIC IV®

About Labatec Pharma

Labatec Pharma is a mature, private Swiss pharmaceutical company with a significant commercial footprint, leveraging its established Swiss brands and extensive network to market a broad portfolio of over 65 products. Its business model is centered on commercializing and distributing small molecule therapeutics, primarily through in-licensing and partnerships, as evidenced by recent deals like the one for MAXIGESIC IV®. The company is revenue-generating, with a strategic focus on expanding its geographic reach in both developed European and high-growth emerging markets.

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals is a publicly traded Belgian company with a mission to address significant healthcare gaps by innovating upon existing medicines. Its core strategy leverages the FDA's 505(b)(2) pathway and equivalents to develop value-added medicines with potentially shorter timelines and lower risk. Key achievements include a broad portfolio of over 30 product candidates, with two products—Sotalol IV and Maxigesic® IV—in early commercialization via partners, positioning it as a leader in this specialized development niche.

About AFT Pharmaceuticals

AFT Pharmaceuticals is a publicly listed, integrated pharmaceutical company with a mission to develop and commercialize innovative products that address unmet health needs. Founded in 1997, it has achieved consistent revenue growth by leveraging a dual strategy of in-licensing/distribution and proprietary R&D, most notably with its world-first Maxigesic® combination analgesic platform. The company has successfully expanded from its New Zealand base to establish a significant presence in Australia, Asia, and Europe, demonstrating robust commercial execution and a focus on niche therapeutic areas like pain management, ophthalmology, and gastroenterology.

Therapeutic Areas

Other Post-operative pain Drugs